7 DRUG INTERACTIONS

One of the key secondary endpoints in this study was Question 3 of the Sexual Encounter Profile diary (SEP3). Timing of sexual activity was not restricted relative to when patients took tadalafil tablets.The efficacy results for patients with both ED and BPH, who received either tadalafil tablet 5 mg for once daily use or placebo (N=408) are shown in Tables 21 and 22 and Figure 8.Tadalafil tablet 5 mg for once daily use resulted in statistically significant improvements in the total IPSS and in the EF domain of the IIEF questionnaire.

5.5 Hypotension when Co-administered with Alpha-blockers or Anti-hypertensives

Table 11: Mean Endpoint and Change from Baseline for the Primary Efficacy Variables in the Two Primary US Trials Results in General ED Population in Trials Outside the US - The 5 primary efficacy and safety studies conducted in the general ED population outside the US included 1112 patients, with a mean age of 59 years (range 21 to 82 years). Table 12: Mean Endpoint and Change from Baseline for the EF Domain of the IIEF in the General ED Population in Five Primary Trials Outside the US aTreatment duration in Study F was 6 months Table 13: Mean Post-Baseline Success Rate and Change from Baseline for SEP Question 2 (“Were you able to insert your penis into the partner’s vagina?”) in the General ED Population in Five Pivotal Trials Outside the US aTreatment duration in Study F was 6 months Table 14: Mean Post-Baseline Success Rate and Change from Baseline for SEP Question 3 (“Did your erection last long enough for you to have successful intercourse?”) in the General ED Population in Five Pivotal Trials Outside the US aTreatment duration in Study F was 6 months In addition, there were improvements in EF domain scores, success rates based upon SEP Questions 2 and 3, and patient-reported improvement in erections across patients with ED of all degrees of disease severity while taking tadalafil tablets, compared to patients on placebo. Therefore, in all 7 primary efficacy and safety studies, tadalafil tablets showed statistically significant improvement in patients’ ability to achieve an erection sufficient for vaginal penetration and to maintain the erection long enough for successful intercourse, as measured by the IIEF questionnaire and by SEP diaries. Efficacy Results in ED Patients with Diabetes Mellitus - Tadalafil tablets were shown to be effective in treating ED in patients with diabetes mellitus. In this randomized, placebo-controlled, double-blinded, parallel-arm design prospective trial, tadalafil tablets demonstrated clinically meaningful and statistically significant improvement in erectile function, as measured by the EF domain of the IIEF questionnaire and Questions 2 and 3 of the SEP diary (see Table 15).

Overall Rating

Table 15: Mean Endpoint and Change from Baseline for the Primary Efficacy Variables in a Study in ED Patients with Diabetes Efficacy Results in ED Patients following Radical Prostatectomy - Tadalafil tablets were shown to be effective in treating patients who developed ED following bilateral nerve-sparing radical prostatectomy. In 1 randomized, placebo-controlled, double-blinded, parallel-arm design prospective trial in this population (N=303), tadalafil tablets demonstrated clinically meaningful and statistically significant improvement in erectile function, as measured by the EF domain of the IIEF questionnaire and Questions 2 and 3 of the SEP diary (see Table 16). Results in Studies to Determine the Optimal Use of Tadalafil Tablets- Several studies were conducted with the objective of determining the optimal use of viagra click and collect tadalafil tablets in the treatment of ED. At or prior to 30 minutes, 35% (26/74), 38% (28/74), and 52% (39/75) of patients in the placebo, 10-mg, and 20-mg groups, respectively, reported successful erections as defined above. Two studies were conducted to assess the efficacy of tadalafil tablets at a given time point after dosing, specifically at 24 hours and at 36 hours after dosing.

Viagra 100mg Tablet

In the first of these studies, 348 patients with ED were randomized to placebo or tadalafil tablets 20 mg. At the 36-hour time point (more specifically, 33 hours to 39 hours), 49/133 (37%) of patients reported at least 1 successful intercourse in the placebo group versus 88/137 (64%) in the tadalafil tablets 20-mg group. In the second of these studies, a total of 483 patients were evenly randomized to 1 of 6 groups: 3 different dosing groups (placebo, tadalafil tablets 10 mg, or 20 mg) that were instructed to attempt intercourse at 2 different times (24 hours and 36 hours post-dosing). At the 36-hour time point, the mean, per-patient percentage of attempts resulting in successful intercourse were 33%, 56%, and 62% for placebo, tadalafil tablets 10-mg, and 20-mg groups, respectively. The efficacy and safety of tadalafil tablet for once daily use in the treatment of erectile dysfunction has been evaluated in 2 clinical trials of 12-weeks duration and 1 clinical trial of 24-weeks duration, involving a total of 853 patients. Tadalafil tablet 5 mg for once daily use also resulted in statistically significant improvement in SEP3. Tadalafil tablets 2.5 mg did not result in statistically significant improvement in the total IPSS.Table 21: Mean IPSS and IIEF EF Domain Changes in the Tadalafil Tablet 5 mg for Once Daily Use Study in Patients with ED and BPHTable 22: Mean SEP Question 3 Changes in the Tadalafil Tablet 5 mg for Once Daily Use Study in Patients with ED and BPHTadalafil tablet for once daily use resulted in improvement in the IPSS total score at the first scheduled observation (week 2) and throughout the 12 weeks of treatment (see Figure 8).In this study, the effect of tadalafil tablet 5 mg once daily on Qmax was evaluated as a safety endpoint.

Mean Qmax increased from baseline in both the treatment and placebo groups (tadalafil tablet 5 mg: 1.6 mL/sec, placebo: 1.2 mL/sec); however, these changes were not significantly different between groups.

Pros and cons of Tadalafil (Cialis)

One of the key secondary endpoints in this study was Question 3 of the Sexual Encounter Profile diary (SEP3). Timing of sexual activity was not restricted relative to when patients took tadalafil tablets.The efficacy results for patients with both ED and BPH, who received either tadalafil tablet 5 mg for once daily use or placebo (N=408) are shown in Tables 21 and 22 and Figure 8.Tadalafil tablet 5 mg for once daily use resulted in statistically significant improvements in the total IPSS and in the EF domain of the IIEF questionnaire. Tadalafil tablet 5 mg for once daily use also resulted in statistically significant improvement in SEP3. Tadalafil tablets 2.5 mg did not result in statistically significant improvement in the total IPSS.Table 21: Mean IPSS and IIEF EF Domain Changes in the Tadalafil Tablet 5 mg for Once Daily Use Study in Patients with ED and BPHTable 22: Mean SEP Question 3 Changes in the Tadalafil Tablet 5 mg for Once Daily Use Study in Patients with ED and BPHTadalafil tablet for once daily use resulted in improvement in the IPSS total score at the first scheduled observation (week 2) and throughout the 12 weeks of treatment (see Figure 8).In this study, the effect of tadalafil tablet 5 mg once daily on Qmax was evaluated as a safety endpoint. Mean Qmax increased from baseline in both the treatment and placebo groups (tadalafil tablet 5 mg: 1.6 mL/sec, placebo: 1.2 mL/sec); however, these changes were not significantly different between groups.

What should I tell my healthcare provider before using tadalafil?

The efficacy and safety of tadalafil in the treatment of erectile dysfunction has been evaluated in 22 clinical trials of up to 24-weeks duration, involving over 4000 patients. Tadalafil tablets, when taken as needed up to once per day, was shown to be effective in improving erectile function in men with erectile dysfunction (ED). Tadalafil tablets were studied in the general ED population in 7 randomized, multicenter, double-blinded, placebo-controlled, parallel-arm design, primary efficacy and safety studies of 12-weeks duration. Additional efficacy and safety studies were performed in ED patients with diabetes mellitus and in patients who developed ED status post bilateral nerve-sparing radical prostatectomy. In these 7 trials, tadalafil tablets were taken as needed, at doses ranging from 2.5 mg to 20 mg, up to once per day.

Patient resources

Food and alcohol intake were not restricted. Several assessment tools were used to evaluate the effect of tadalafil tablets on erectile function. SEP Question 2 asks, “Were you able to insert your penis into the partner’s vagina?” SEP Question 3 asks, “Did your erection last long enough for you to have successful intercourse?” The overall percentage of successful attempts to insert the penis into the vagina (SEP2) and to maintain the erection for successful intercourse (SEP3) is derived for each patient. Results in ED Population in US Trials - The 2 primary US efficacy and safety trials included a total of 402 men with erectile dysfunction, with a mean age of 59 years (range 27 to 87 years). The treatment effect of tadalafil tablets did not diminish over time. The efficacy and safety of tadalafil in the treatment of erectile dysfunction has been evaluated in 22 clinical trials of up to 24-weeks duration, involving over 4000 patients. Tadalafil tablets, when taken as needed up to once per day, was shown to be effective in improving erectile function in men with erectile dysfunction (ED). Tadalafil tablets were studied in the general ED population in 7 randomized, multicenter, double-blinded, placebo-controlled, parallel-arm design, primary efficacy and safety studies of 12-weeks duration. Additional efficacy and safety studies were performed in ED patients with diabetes mellitus and in patients who developed ED status post bilateral nerve-sparing radical prostatectomy. In these 7 trials, tadalafil tablets were taken as needed, at doses ranging from 2.5 mg to 20 mg, up to once per day. Food and alcohol intake were not restricted. Several assessment tools were used to evaluate the effect of tadalafil tablets on erectile function. SEP Question 2 asks, “Were you able to insert your penis into the partner’s vagina?” SEP Question 3 asks, “Did your erection last long enough for you to have successful intercourse?” The overall percentage of successful attempts to insert the penis into the vagina (SEP2) and to maintain the erection for successful intercourse (SEP3) is derived for each patient.

Results in ED Population in US Trials - The 2 primary US efficacy and safety trials included a total of 402 men with erectile dysfunction, with a mean age of 59 years (range 27 to 87 years). The treatment effect of tadalafil tablets did not diminish over time. Table 11: Mean Endpoint and Change from Baseline for the Primary Efficacy Variables in the Two Primary US Trials Results in General ED Population in Trials Outside the US - The 5 primary efficacy and safety studies conducted in the general ED population outside the US included 1112 patients, with a mean age of 59 years (range 21 to 82 years). Table 12: Mean Endpoint and Change from Baseline for the EF Domain of the IIEF in the General ED Population in Five Primary Trials Outside the US aTreatment duration in Study F was 6 months Table 13: Mean Post-Baseline Success Rate and Change from Baseline for SEP Question 2 (“Were you able to insert your penis into the partner’s vagina?”) in the General ED Population in Five Pivotal Trials Outside the US aTreatment duration in Study F was 6 months Table 14: Mean Post-Baseline Success Rate and Change from Baseline for SEP Question 3 (“Did your erection last long enough for you to have successful intercourse?”) in the General ED Population in Five Pivotal Trials Outside the US aTreatment duration in Study F was 6 months In addition, there were improvements in EF domain scores, success rates based upon SEP Questions 2 and 3, and patient-reported improvement in erections across patients with ED of all degrees of disease severity while taking tadalafil tablets, compared to patients on placebo. Therefore, in all 7 primary efficacy and safety studies, tadalafil tablets showed statistically significant improvement in patients’ ability to achieve an erection sufficient for vaginal penetration and to maintain the erection long enough for successful intercourse, as measured by the IIEF questionnaire and by SEP diaries.

• The yellow Viagra pill is sometimes marketed as a generic or branded version.
• Its effectiveness depends on the individual's health and dosage taken.
• Store the pill in a cool, dry place away from direct sunlight.
• The pill may be taken with or without food, but high-fat meals can delay effects.
• Some yellow Viagra tablets contain 25mg, 50mg, or 100mg of sildenafil.
• Always follow prescribed doses; overdosing can lead to severe health risks.

Efficacy Results in ED Patients with Diabetes Mellitus - Tadalafil tablets were shown to be effective in treating ED in patients with diabetes mellitus.

In this randomized, placebo-controlled, double-blinded, parallel-arm design prospective trial, tadalafil tablets demonstrated clinically meaningful and statistically significant improvement in erectile function, as measured by the EF domain of the IIEF questionnaire and Questions 2 and 3 of the SEP diary (see Table 15). Table 15: Mean Endpoint and Change from Baseline for the Primary Efficacy Variables in a Study in ED Patients with Diabetes Efficacy Results in ED Patients following Radical Prostatectomy - Tadalafil tablets were shown to be effective in treating patients who developed ED following bilateral nerve-sparing radical prostatectomy. In 1 randomized, placebo-controlled, double-blinded, parallel-arm design prospective trial in this population (N=303), tadalafil tablets demonstrated clinically meaningful and statistically significant improvement in erectile function, as measured by the EF domain of the IIEF questionnaire and Questions 2 and 3 of the SEP diary (see Table 16). Results in Studies to Determine the Optimal Use of Tadalafil Tablets- Several studies were conducted with the objective of determining the optimal use of viagra click and collect tadalafil tablets in the treatment of ED. At or prior to 30 minutes, 35% (26/74), 38% (28/74), and 52% (39/75) of patients in the placebo, 10-mg, and 20-mg groups, respectively, reported successful erections as defined above.

Two studies were conducted to assess the efficacy of tadalafil tablets at a given time point after dosing, specifically at 24 hours and at 36 hours after dosing. In the first of these studies, 348 patients with ED were randomized to placebo or tadalafil tablets 20 mg.

• The color yellow helps distinguish Viagra pills from other ED medications.
• Some yellow Viagra tablets are designed for extended-release effects.
• It's essential to purchase from reliable sources to avoid counterfeit pills.
• Viagra works by inhibiting an enzyme called PDE5, enhancing blood flow.
• Missing doses or inconsistent use can reduce treatment effectiveness.
• Always read the patient information leaflet included with the pill.

At the 36-hour time point (more specifically, 33 hours to 39 hours), 49/133 (37%) of patients reported at least 1 successful intercourse in the placebo group versus 88/137 (64%) in the tadalafil tablets 20-mg group. In the second of these studies, a total of 483 patients were evenly randomized to 1 of 6 groups: 3 different dosing groups (placebo, tadalafil tablets 10 mg, or 20 mg) that were instructed to attempt intercourse at 2 different times (24 hours and 36 hours post-dosing). At the 36-hour time point, the mean, per-patient percentage of attempts resulting in successful intercourse were 33%, 56%, and 62% for placebo, tadalafil tablets 10-mg, and 20-mg groups, respectively.

• The impact of the yellow Viagra pill can vary based on physical health and age.
• Its use is not recommended for individuals taking certain antifungals or antibiotics.
• The pill is effective only if the underlying cause of ED is suitable for sildenafil.
• Discreet packaging is common for online purchases of yellow Viagra pills.
• The pill’s effectiveness may diminish over time or with inconsistent use.
• Consult your doctor if you experience no results or adverse effects.

The efficacy and safety of tadalafil tablet for once daily use in the treatment of erectile dysfunction has been evaluated in 2 clinical trials of 12-weeks duration and 1 clinical trial of 24-weeks duration, involving a total of 853 patients. Tadalafil tablet, when taken once daily, was shown to be effective in improving erectile function in men with erectile dysfunction (ED). a Twenty-four-week study conducted in the US. The efficacy and safety of tadalafil tablet for once daily use for the treatment of the signs and symptoms of BPH was evaluated in 3 randomized, multinational, double-blinded, placebo-controlled, parallel-design, efficacy and safety studies of 12 weeks duration.

• Yellow Viagra should be stored out of reach of children and pets.
• It is not suitable for use in individuals with severe hypotension or stroke history.
• The medication can cause priapism, a prolonged erection that requires medical attention.
• Do not take yellow Viagra if you are allergic to sildenafil or other ingredients.
• The pill's nutritional compatibility is generally unaffected by diet unless high-fat.
• Discontinue use and seek medical help if adverse reactions occur.

Patients with multiple co-morbid conditions such as diabetes mellitus, hypertension, and other cardiovascular disease were included.

7.1 Nitrates

The primary efficacy endpoint in the two studies that evaluated the effect of tadalafil tablets for the signs and symptoms of BPH was the International Prostate Symptom Score (IPSS), a four week recall questionnaire that was administered at the beginning and end of a placebo run-in period and subsequently at follow-up visits after randomization. Maximum urinary flow rate (Qmax), an objective measure of urine flow, was assessed as a secondary efficacy endpoint in Study J and as a safety endpoint in Study K. The results for BPH patients with moderate to severe symptoms and a mean age of 63.2 years (range 44 to 87) who received either tadalafil tablet 5 mg for once daily use or placebo (N=748) in Studies J and K are shown in Table 19 and Figures 5 and 6, respectively. In each of these 2 trials, tadalafil tablet 5 mg for once daily use resulted in statistically significant improvement in the total IPSS compared to placebo. Mean total IPSS showed a decrease starting at the first scheduled observation (4 weeks) in Study K and remained decreased through 12 weeks. In Study J, the effect of tadalafil tablet 5 mg once daily on maximum urinary flow rate (Qmax) was evaluated as a secondary efficacy endpoint. In Study K, the effect of tadalafil tablet 5 mg once daily on Qmax was evaluated as a safety endpoint. Mean Qmax increased from baseline in both the treatment and placebo groups (tadalafil tablet 5 mg: 1.6 mL/sec, placebo: 1.1 mL/sec); however, these changes were not significantly different between groups.

17.4 Concomitant Use with Drugs Which Lower Blood Pressure

Tadalafil tablet, when taken once daily, was shown to be effective in improving erectile function in men with erectile dysfunction (ED). a Twenty-four-week study conducted in the US. The efficacy and safety of tadalafil tablet for once daily use for the treatment of the signs and symptoms of BPH was evaluated in 3 randomized, multinational, double-blinded, placebo-controlled, parallel-design, efficacy and safety studies of 12 weeks duration. Patients with multiple co-morbid conditions such as diabetes mellitus, hypertension, and other cardiovascular disease were included. The primary efficacy endpoint in the two studies that evaluated the effect of tadalafil tablets for the signs and symptoms of BPH was the International Prostate Symptom Score (IPSS), a four week recall questionnaire that was administered at the beginning and end of a placebo run-in period and subsequently at follow-up visits after randomization.

Marketing and sales

Maximum urinary flow rate (Qmax), an objective measure of urine flow, was assessed as a secondary efficacy endpoint in Study J and as a safety endpoint in Study K. The results for BPH patients with moderate to severe symptoms and a mean age of 63.2 years (range 44 to 87) who received either tadalafil tablet 5 mg for once daily use or placebo (N=748) in Studies J and K are shown in Table 19 and Figures 5 and 6, respectively. In each of these 2 trials, tadalafil tablet 5 mg for once daily use resulted in statistically significant improvement in the total IPSS compared to placebo. Mean total IPSS showed a decrease starting at the first scheduled observation (4 weeks) in Study K and remained decreased through 12 weeks. In Study J, the effect of tadalafil tablet 5 mg once daily on maximum urinary flow rate (Qmax) was evaluated as a secondary efficacy endpoint.

Jet lag research

In Study K, the effect of tadalafil tablet 5 mg once daily on Qmax was evaluated as a safety endpoint. Mean Qmax increased from baseline in both the treatment and placebo groups (tadalafil tablet 5 mg: 1.6 mL/sec, placebo: 1.1 mL/sec); however, these changes were not significantly different between groups. Efficacy Results in Patients with BPH initiating Tadalafil Tablets and Finasteride – Tadalafil tablet for once daily use initiated together with finasteride was shown to be effective in treating the signs and symptoms of BPH in men with an enlarged prostate (>30 cc) for up to 26 weeks. Patients with multiple co-morbid conditions such as erectile dysfunction, diabetes mellitus, hypertension, and other cardiovascular disease were included. Efficacy Results in Patients with BPH initiating Tadalafil Tablets and Finasteride – Tadalafil tablet for once daily use initiated together with finasteride was shown to be effective in treating the signs and symptoms of BPH in men with an enlarged prostate (>30 cc) for up to 26 weeks. Patients with multiple co-morbid conditions such as erectile dysfunction, diabetes mellitus, hypertension, and other cardiovascular disease were included.